An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents
Helicobacter · 2026
DOI: 10.1111/hel.70103 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2026. Verfasst von Anja Šterbenc und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Helicobacter Infections, Anti-Bacterial Agents, Helicobacter pylori, Bismuth. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Javna Agencija za Raziskovalno Dejavnost RS, The Slovenian Research and Innovation Agency.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
To achieve eradication rates > 90%, the ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori infection recommend tailored antimicrobial therapy using sufficiently high doses over 10–14 days. However, prolonged treatment often leads to suboptimal compliance in children, which is a major contributor to reduced eradication rates. To address this, we evaluated the efficacy and safety of a shorter, 7 day triple therapy with bismuth compared with the 14 day standard triple therapy without bismuth in H. pylori infected children. Materials and Methods From 2020 to 2024, we carried out a randomized controlled trial involving treatment‐naïve children and adolescents (5–18 years old) with confirmed H. pylori infection. Eligible participants were randomly allocated to receive either a 7 day triple therapy with bismuth (bismuth subcitrate, a proton pump inhibitor [PPI], amoxicillin, plus clarithromycin/metronidazole) or a 14 day standard triple therapy (a PPI, amoxicillin, plus clarithromycin/metronidazole) without bismuth. Two months after completing therapy, treatment success was determined using either a two‐step monoclonal stool antigen assay or a urea breath test. Any adverse events were documented using a structured questionnaire.
Results
Seventy‐three children were enrolled in the study. In the intention‐to‐treat analysis, eradication was achieved in 91% of children treated with the 7 day triple therapy with bismuth and 87% of those receiving the 14 day standard triple therapy ( p = 0.695). Per‐protocol eradication rates were 94% and 87%, respectively ( p = 0.418). No serious adverse events were reported, and most adverse events were mild to moderate. A metallic taste was significantly more frequent in the 14 day standard triple therapy group, while other adverse events occurred with similar frequency.
Conclusions
Adding bismuth to a 7 day triple regimen achieved high eradication rates and a safety profile similar to 14 day standard triple therapy, supporting its use as an effective and safe treatment option for pediatric H. pylori infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Institute for Biostatistics and Medical Informatics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Department of Pediatrics, Slovenj Gradec General Hospital, Slovenj Gradec, Slovenia.
- Department of Gastroenterology, Hepatology, and Nutrition, University Children's Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
ORCID-Profile: Matjaž Homan
Förderung
- Javna Agencija za Raziskovalno Dejavnost RS
- The Slovenian Research and Innovation Agency
Zitieren
APA
Šterbenc, A., Vratanar, B., Mojškerc, E. M., & Homan, M. (2026). An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents. Helicobacter. https://doi.org/10.1111/hel.70103
Vancouver
Šterbenc A, Vratanar B, Mojškerc EM, Homan M. An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents. Helicobacter. 2026. doi:10.1111/hel.70103
BibTeX
@article{terbenc2026,
author = {Šterbenc, Anja and Vratanar, Bor and Mojškerc, Eva Miler and Homan, Matjaž},
title = {An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents},
journal = {Helicobacter},
year = {2026},
doi = {10.1111/hel.70103}
}
EUVIMED